Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Treosulfan Conditioning for Nijmegen Breakage Syndrome
NCT06198842Phase 2Recruiting
- Sponsor
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
- Start
- Nov 2023
- Primary completion
- Jan 2027
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of treosulfan in Nijmegen breakage syndrome (NBS), sponsored by Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Primary endpoint: Event-free survival at 3 years. Started Nov 2023; status: recruiting.
02
Drugs
treosulfan
03
Conditions
Nijmegen breakage syndrome (NBS)
Beyond the preview
Go deeper on NCT06198842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06198842.